Antitumor efficacy of DMSA modified Fe3O4 magnetic nanoparticles combined with arsenic trioxide and adriamycin in Raji cells

Journal of Biomedical Nanotechnology

Volumn 10, Issue 2, 2014, Pages 251-261

  Cai, Xiaohui ^a   Wang, Chunling ^a   Chen, Baoan ^b   Hua, Weijun ^c   Shen, Fei ^a   Yu, Liang ^b   He, Zhengmei ^b   Shi, Yuye ^b   Chen, Yue ^b   Xia, Guohua ^a   Cheng, Jian ^a   Bao, Wen ^a   Zhang, Yu ^d   Wang, Xuemei ^e  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c JIANGSU UNIVERSITY   (China)

^d Southeast University   (China)

^e SOUTHEAST UNIVERSITY   (China)

Author keywords

ADM; As 2o3; Bax; Bcl 2; Caspase 3; DMSA Fe3o4; Magnetic nanoparticles; Nf b; P53; Survivin

Indexed keywords

BAX; BCL-2; CASPASE-3; DMSA-FE3O4; MAGNETIC NANO-PARTICLES; P53; SURVIVIN;

ARSENIC; CELL CULTURE; CELL DEATH; DELTA MODULATION; ONCOLOGY; POLYMERASE CHAIN REACTION; PROTEINS; TRANSCRIPTION; TRANSMISSION ELECTRON MICROSCOPY;

NANOPARTICLES;

4',6 DIAMIDINO 2 PHENYLINDOLE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CASPASE 3; DIMERCAPTOSUCCINIC ACID MODIFIED IRON OXIDE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAGNETIC NANOPARTICLE; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG POTENTIATION; ENDOSOME; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MTT ASSAY; NONHODGKIN LYMPHOMA; PARTICLE SIZE; PROTEIN EXPRESSION; RAJI CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; DOXORUBICIN; FERRIC COMPOUNDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SPACE; MAGNETITE NANOPARTICLES; OXIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; SUCCIMER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893206408     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1787     Document Type: Article

References (64)

1. R. Siegel, D. Naishadham, and A. Jemal, Cancer statistics. CA Cancer J. Clin. 62, 10 (2012).
2. K. Van Besien, Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr. Opin. Oncol. 23, 681 (2011).
3. E. Fox, B. I. Razzouk, B. C. Widemann, S. Xiao, M. O'Brien, W. Goodspeed, G. H. Reaman, S. M. Blaney, A. J. Murgo, F. M. Balis, and P. C. Adamson, Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 111, 566 (2008).
4. G. Orive, A. R. Gascon, R. M. Hernandez, A. Dominguez-Gil, and J. L. Pedraz, Techniques: New approaches to the delivery of biopharmaceuticals. Trends Pharm. Sci. 25, 382 (2004).
5. B. Koppolu, Z. Bhavsar, A. S. Wadajkar, S. Nattama, M. Rahimi, F. Nwariaku, and K. T. Nguyen, Temperature-sensitive polymercoated magnetic nanoparticles as a potential drug delievery system for targeted therapy of thyroid cancer. J. Biomed. Nanotechnol. 8, 983 (2012).
6. M. Mahmoudi, S. Sant, B. Wang, S. Laurent, and T. Sen, Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy. Adv. Drug Deliv. Rev. 63, 24 (2011).
7. A. J. Cole, V. C. Yang, and A. E. David, Cancer theranostics: The rise of targeted magnetic nanoparticles. Trends Biotechnol. 29, 323 (2011).
8. J. T. Jang, H. Nah, J. H. Lee, S. H. Moon, M. G. Kim, and J. Cheon, Critical enhancements of MRI contrast and hyperthermic effects by dopant-controlled magnetic nanoparticles. Angew. Chem. Int. Ed. Engl. 48, 1234 (2009).
9. M. C. Franchini, G. Baldi, D. Bonacchi, D. Gentili, G. Giudetti, A. Lascialfari, M. Corti, P. Marmorato, J. Ponti, E. Micotti, U. Guerrini, L. Sironi, P. Gelosa, C. Ravagli, and A. Ricci, Bovine serum albumin-based magnetic nanocarrier for MRI diagnosis and hyperthermic therapy: A potential theranostic approach against cancer. Small 6, 366 (2010).
10. Y. J. Tang, Z. Y. Li, and N. Y. He, Preparation of functional magnetic nanoparticles mediated with PEG-4000 and application in pseudomonas aeruginosa rapid detection. J. Biomed. Nanotechnol. 9, 321 (2013).
11. S. Li, H. N. Liu, Y. Y. Jia, X. B. Mou, Y. Deng, L. Lin, and N. Y. He, An automatic high-throughput SNP genotyping approach based on universal tagged arrays and magnetic nanoparticles. J. Biomed. Nanotechnol. 9, 689 (2013).
12. S. Li, H. N. Liu, Y. Deng, L. Lin, and N. Y. He, Development of a magnetic nanoparticles microarray for simultaneous and simple detection of foodborne pathogens. J. Biomed. Nanotechnol. 9, 1254 (2013).
13. F. Wang, C. Ma, X. Zeng, C. Y. Li, Y. Deng, and N. Y. He, Chemiluminescence molecular detection of sequence-special HBV-DNA using magnetic nanoparticles. J. Biomed. Nanotechnol. 8, 786 (2012).
14. M. Chanana, Z. W. Mao, and D. Y. Wang, Using polymers to make up magnetic nanoparticles for biomedicine. J. Biomed. Naonotechnol. 5, 652 (2009).
15. D. A. Mbeh, R. Franca, Y. Merhi, X. F. Zhang, T. Veres, E. Sacher, and L. Yahia, In vitro biocompatibility assessment of functionalized magnetite nanoparticles: Biological and cytotoxicological effects. J. Biomed. Mater. Res. A 100A, 1637 (2012).
16. R. R. Qiao, J. F. Zeng, Q. J. Jia, J. Du, L. Shen, and M. Y. Gao, Magnetic iron oxide nanoparticle-an important cornerstone of MR molecular imaging of tumors. Acta Phys.-Chim. Sin. 28, 993 (2012).
17. X. Q. Zhang, L. Jiang, C. L. Zhang, D. Li, C. Wang, F. Gao, and D. X. Cui, A silicon dioxide modified magnetic nanoparticles-labeled flow strip for HBs antigen. J. Biomed. Nanotechnol. 7, 776 (2011).
18. 2 Microspheres and its application for magnetic separation of nucleic acids from E. coli BL21. J. Biomed. Nanotechnol. 8, 1000 (2012).
19. R. R. Oliveira, F. S. Ferreira, E. R. Cintra, L. C. Branquinho, A. F. Bakuzis, and E. M. Lima, Magnetic nanopariticles and rapamycin encapsulated into polymeric nanocarriers. J. Biomed. Nanotechnol. 8, 193 (2012).
20. R. Singh and H. S. Nalwa, Medical applications of nanoparticles in biological imaging, cell labeling, antimicrobial agents and anticancer nanodrugs. J. Biomed. Nanotechnol. 7, 489 (2011).
21. Z. P. Chen, Y. Zhang, S. Zhang, J. G. Xia, J. W. Liu, K. Xu, and N. Gu, Preparation and characterization of water-soluble monodisperse magnetic iron oxide nanoparticles via surface double-exchange with DMSA. Colloid Surface A 316, 210 (2008).
22. H. E. Daldrup-Link, E. J. Rummeny, B. Ihssen, J. Kienast, and T. M. Link, Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: Differentiation between tumor infiltration and hypercellular bone marrow. Eur. Radiol. 12, 1557 (2002).
23. A. Luchetti, D. Milani, F. Ruffini, R. Galli, A. Fallini, A. Quattrini, G. Scotti, G. Comi, G. Martino, R. Furlan, and L. S. Politi, Monoclonal antibodies conjugated with superparamagnetic rion oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain. Mol. Imaging 11, 114 (2012).
24. G. Baio, M. Fabbi, S. Salvi, D. de Totero, M. Truini, S. Ferrini, and C. E. Neumaier, Two-step in vivo tumor targeting by biotin-conjugated antibodies and superparamagnetic nanoparticles assessed by magnetic resonance imaging at 1.5T. Mol. Imaging Biol. 12, 305 (2010).
25. Z. P. Chen, Y. Zhang, K. Xu, R. Z. Xu, J. W. Liu, and N. Gu, Stability of hydrophilic magnetic nanoparticles under biologically relevant conditions. J. Nanosci. Nanotechnol. 8, 6260 (2008).
26. S. Zhang, Z. P. Bian, C. R. Gu, Y. Zhang, S. Y. He, N. Gu, and J. N. Zhang, Preparation of anti-human cardiac troponin I immunomagnetic nanoparticles and biological activity assays. Colloid Surface B 55, 143 (2007).
27. Z. P. Chen, Y. Zhang, J. G. Xia, J. W. Liu, K. Xu, and N. Gu, Preparation and characterization of water-soluble monodisperse magnetic iron nanoparticles via surface double-exchange with DMSA. Colloid Surface. A 316, 210 (2008).
28. 4 nanoparticles loaded with cisplatin onSKOV3/DDP ovarian carcinoma cells. Int. J. Nanomed. 4, 107 (2009).
29. 4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells. Int. J. Nanomed. 4, 209 (2009).
30. V. T. DeVita, Dose-response is alive and well. J. Clin. Oncol. 4, 1157 (1986).
31. J. X. Liu, G. B. Zhou, S. J. Chen, and Z. Chen, Arsenic compounds: Revived ancient remedies in the fight against human malignancies. Curr. Opin. Chem. Biol. 16, 92 (2012).
32. C. B. Thompson, Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456 (1995).
33. Y. A. Hannum, Apoptosis and the dilemma of cancer therapy. Blood 89, 1846 (1997).
34. M. A. Barry, C. A. Behnke, and A. Eastman, Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40, 2353 (1990).
35. H. Lu, G. X. Yuan, and Q. H. He, Rapid analysis of anthracycline antibiotics doxorubicin and daunorubicin by microchip capillary electrophoresis. Microchem. J. 92, 170 (2009).
36. D. F. Zhao, Y. F. Jiang, X. Y. Dong, Z. L. Liu, B. B. Qu, Y. F. Zhang, N. Ma, and Q. K. Han, Arsenic trioxide reduces drug resistance to adriamycin in leukemic K562/A02 cells via multiple mechanisms. Biomed. Pharm. 65, 354 (2011).
37. G. M. Sledge and K. D. Miller, Exploiting the hallmarks of cancer: The future conquest of breast cancer. Eur. J. Cancer 39, 1668 (2003).
38. T. M. Allen and P. R. Cullis, Drug delivery systems: Entering the mainstream. Science 303, 1818 (2004).
39. M. Conti, V. Tazzari, C. Baccini, G. Petici, L. P. Serino, and U. De Giorgi, Anticancer drug delivery with nanoparticles. In Vivo 20, 697 (2006).
40. A. K. Iyer, G. Khaled, J. Fang, and H. Maeda, Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11, 812 (2006).
41. Y. Liu, H. Miyoshi, and M. Nakamura, Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer 120, 2527 (2007).
42. K. K. Jain, Nanomedicine: Application of nanobiotechnology in medical practice. Med. Princ. Pract. 17, 89 (2008).
43. T. M. Allen, Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750 (2002).
44. 4 nanoparticles with 2-methoxyestradiol on the cell-cycle progression and apoptosis of myelodysplastic syndrome cells. Int. J. Nanomed. 6, 1921 (2011).
45. L. Wang, H. J. Zhang, B. A. Chen, G. H. Xia, S. Wang, J. Cheng, Z. Y. Shao, C. Gao, W. Bao, L. Tian, Y. Y. Ren, P. P. Xu, X. H. Cai, R. Liu, and X. M. Wang, Effect of magnetic nanoparticles on apoptosis and cell cycle induced by wogonin in raji cells. Int. J. Nanomed. 7, 789 (2012).
46. 4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line. Int. J. Nanomed. 7, 2843 (2012).
47. A. K. Gupta and S. Wells, Surface-modified superparamagnetic nanoparticles for drug delivery: Preparation, characterization, and cytotoxicity studies. IEEE Trans. Nanobioscience 3, 66 (2004).
48. P. P. Babu, G. Suzuki, Y. Ono, and Y. Yoshida, Attenuation of ischemia and/or reperfusion injury during myocardial infarction using mild hypothermia in rats: An immunohistochemical study of Bcl-2, Bax, Bak and TUNEL. Pathol. Int. 54, 896 (2004).
49. I. A. Voutsadakis, Apoptosis and the pathogenesis of lymphoma. Acta Oncol. 39, 151 (2000).
50. E. A. Schon and G. Manfredi, Neuronal degeneration and mitochondrial dysfunction. J. Clin. Invest. 111, 303 (2003).
51. Z. L. Xie, T. Koyama, J. Suzuki, Y. Fujii, H. Togashi, H. Sawa, and K. Nagashima, Coronary reperfusion following ischemia: Different expression of bcl-2 and bax proteins and cardiomyocyte apoptosis. Jpn. Heart. J. 42, 759 (2001).
52. D. S. McClintock, M. T. Santore, V. Y. Lee, J. Brunelle, G. R. S. Budinger, W. X. Zong, C. B. Thompson, N. Hay, and N. S. Chandel, Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death. Mol. Cell. Biol. 22, 94 (2002).
53. A. C. Mita, M. M. Mita, S. T. Nawrocki, and F. J. Giles, Survivn: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 14, 5000 (2008).
54. A. A. Beg and D. Baltimore, An essential role for NF-kappa B in preventing TNF-alpha-induced cell death. Science 274, 782 (1999).
55. M. S. Hayden and S. Ghosh, Signaling to NF-kappa B. Genes Dev. 18, 2195 (2004).
56. Z. G. Liu, H. Hsu, D. V. Goeddel, and M. Karin, Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappa B activation prevents cell death. Cell 87, 565 (1996).
57. S. Ghosh and M. Karin, Missing pieces in the NF-kappa B puzzle. Cell 109, S81 (2002).
58. M. Karin and F. R. Greten, NF-kappa B: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749 (2005).
59. S. Shishodia and B. B. Aggarwal, Nuclear factor-K B: A friend or a foe in cancer? Biochem. Pharmacol. 68, 1071 (2004).
60. E. S. Hwang, Transcriptional regulation of T helper 17 cell differentiation. Yonsei Med. J. 51, 484 (2010).
61. K. Kawauchi, K. Araki, K. Tobiume, and N. Tanaka, Loss of p53 enhances catalytic activity of IKK beta through O-linked beta-N-acetylglucosamine modification. Pro. Natl. Acad. Sci. USA 106, 3431 (2009).
62. A. R. Tentner, M. J. Lee, G. J. Ostheimer, L. D. Samson, D. A. Lauffenburger, and M. B. Yaffe, Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol. Syst. Biol. 8, 568 (2012).
63. X. S. Wen, D. Li, Y. Y. Zhang, S. P. Liu, L. Ghali, and R. K. IIes, Arsenic trioxide induces cervical cancer apoptosis, but specifically targets human papillomavirus-infected cell populations. Anti-Cancer Drug 23, 280 (2012).
64. X. S. Wu, J. M. Shi, Y. Wu, Y. Tao, J. Hou, X. Q. Meng, X. J. Hu, Y. Hu, W. Jiang, S. Y. Tang, M. Zangari, G. Tricot, and F. H. Zhan, Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol. Ther. 10, 1202 (2010).